Clinical Trials Logo

Refractory Cutaneous Melanoma clinical trials

View clinical trials related to Refractory Cutaneous Melanoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05200143 Active, not recruiting - Clinical trials for Refractory Cutaneous Melanoma

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Start date: June 8, 2022
Phase: Phase 2
Study type: Interventional

The primary objective of this clinical trial is to evaluate the clinical efficacy and progression free survival of the triplet combination of ipilimumab + nivolumab + cabozantinib in patients with anti-PD-1/PD-L1 refractory metastatic cutaneous melanoma.